摘要
目的分析倍他乐克联合可达龙、门冬氨酸钾镁治疗急性心肌梗死合并恶性心律失的临床疗效。方法选择2015年12月至2016年12月医院收治的急性心肌梗死患者82例,依照治疗方式不同分成单治组与联合组,各41例。单治组患者单纯使用倍他乐克治疗,联合组患者应用倍他乐克联合可达龙、门冬氨酸钾镁进行治疗。结果联合组的总有效率高于单治组(P<0.05);联合组患者死亡率低于单治组(P<0.05)。结论倍他乐克联合可达龙、门冬氨酸钾镁治疗急性心肌梗死合并恶性心律失常效果显著,值得推广。
Objective To analyze the effect of metoprolo combined with amiodaronum and potassium magnesium aspartate in the treatment of patients with acute myocardial infarction.Methods From 2015 December to 2016 December,82 patients with acute myocardial infarction in our hospital,according to the different treatment methods they were divided into single treatment group and combined group,41 cases of in each group.The single treatment group was treated with metoprold,the combined group was treated with metoprolo combined with amiodaronum and potassium magnesium aspartate.Results The total effective rate of the combined group was significantly higher than that of the single treatment group(P<0.05).The mortality of the combined group was significantly lower than that of the single treatment group(P<0.05).Conclusion Metoprold combined with amiodaronum and potassium magnesium aspartate in the treatment of acute myocardial infarction is effective,and it is worthy of promotion.
出处
《中国药业》
CAS
2017年第A02期32-33,共2页
China Pharmaceuticals
关键词
倍他乐克
可达龙
门冬氨酸钾镁
临床疗效
metoprold
amiodaronum
potassium magnesium aspartate
clinical effect
